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Abstract
Background: Cellulitis (erysipelas) is a recurring and debilitating bacterial infection of the skin and underlying tissue. We
assessed the cost-effectiveness of prophylactic antibiotic treatment to prevent the recurrence of cellulitis using low dose
penicillin V in patients following a first episode (6 months prophylaxis) and more recurrent cellulitis (12 months prophylaxis,
or 6 months in those declining 12 months).
Methods: Within-trial cost-effectiveness analysis was conducted using the findings of two randomised placebo-controlled
multicentre trials (PATCH I and PATCH II), in which patients recruited in the UK and Ireland were followed-up for up to 3
years. Incremental cost, reduction in recurrence, cost per recurrence prevented and cost/QALY were estimated. National unit
and reference costs for England in 2010 were applied to resource use, exploring NHS and societal perspectives. A total of
397 patients from the two trials contributed to the analysis.
Results: There was a 29% reduction in the number of recurrences occurring within the trial (IRR: 0.71 95%CI: 0.53 to 0.90,
p = 0.02), corresponding to an absolute reduction of recurrence of 0.31 recurrences/patient (95%CI: 0.05 to 0.59, p = 0.02).
Incremental costs of prophylaxis suggested a small cost saving but were not statistically significant, comparing the two
groups. If a decision-maker is willing to pay up to £25,000/QALY then there is a 66% probability of antibiotic prophylaxis
being cost-effective from an NHS perspective, rising to 76% probability from a secondary, societal perspective.
Conclusion: Following first episode or recurrent cellulitis of the leg, prophylactic low dose penicillin is a very low cost
intervention which, on balance, is effective and cost-effective at preventing subsequent attacks. Antibiotic prophylaxis
reduces cellulitis recurrence by nearly a third but is not associated with a significant increase in costs.
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Introduction
Cellulitis (erysipelas) of the leg is a common infection of the skin
and sub-cutaneous tissue that recurs in up to 50% of cases [1], and
is most commonly caused by streptococcal infection [2,3].
Recurrent episodes lead to progressive damage of the lymphatic
system, resulting in lymphedema and increased risk of recurrence
and associated costs of care [4,5]. While antibiotic treatment of an
acute episode of cellulitis is uncontroversial [6], physicians’ views
on whether low dose antibiotics should be used to prevent cellulitis
recurring are variable.
This paper describes a within-trial health economic analysis of
two randomised controlled trials addressing the prevention of
cellulitis, using low dose prophylactic penicillin (PATCH I and
PATCH II) [7,8]. Prior to these trials, the evidence base was
limited to three small inconclusive randomised controlled trials
(120 patients in total) published between 1991 and 1994 [9–11],
with no trial-based economic analysis. Consequently, current
guidance on preventing cellulitis is largely consensus based
[12,13]. In England in 2011, limb cellulitis accounted for 52,654
hospital admissions and 373,343 bed days at an approximate cost
of £120 million [14,15]. Hospitalised patients represent the most
severe cases, although many patients are treated in the commu-
nity. A study in the Netherlands in 2001, found that only 7% of all
patients were hospitalized although 83% of the total treatment
costs occurred in hospital [16].
In brief, the PATCH I and II trials were double-blind, parallel
group, randomised controlled trials comparing low dose penicillin
V (250 mg bd) with matched placebo [used prophylactically] to
prevent recurrence of cellulitis of the leg (PATCH I:
ISRCTN34716921 and PATCH II: ISRCTN03813200) [7,8].
Recruitment occurred in 28 hospitals in the UK and Ireland
between June 2006 and January 2010. Potential participants were
identified for the trials if they had suffered a recent episode of
cellulitis of the leg; they were consented and randomised to
prophylaxis with penicillin or placebo after treatment of the acute
episode had been completed. Both trials followed patients for up to
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three years. PATCH I recruited 274 patients with recurrent
cellulitis who were given 12 months prophylaxis, while PATCH II
recruited 123 patients who were given six months prophylaxis
following a first episode of cellulitis (n = 97) or those with recurrent
cellulitis who refused 12 months of prophylaxis (n = 26). PATCH I
reported a reduced risk of first recurrence during the prophylaxis
phase to 12 months (hazard ratio, HR 0.55, 95% CI 0.35, 0.86;
p = 0.01), with 22% of treated patients having a repeat episode
compared with 37% in the placebo group. PATCH II reported a
reduced risk of first recurrence over the full three year period of
follow-up (hazard ratio, HR: 0.53, 95%CI: 0.26 to 1.07, P= 0.08],
with 20% of treated patients having a repeat episode compared
with 33% in the placebo group.
To inform policy and clinical practice about the cost-
effectiveness of prophylaxis to prevent recurrent cellulitis, an
economic analysis was planned prospectively within the PATCH
trial designs.
Methods
Within-trial patient-level cost-effectiveness analyses were under-
taken using data from the PATCH I and II trials. Patient data
were analysed using the same intention to treat principles applied
to the clinical outcomes. The primary analysis was from the NHS
perspective with a secondary societal analysis. Because of the
similarity of the methods, outcomes and results in the two trials a
patient level analysis was conducted combining the participants of
both PATCH I and II.
Outcomes
Within the clinical trial reports the primary outcome of interest
was time to first recurrence with the relative rate between groups
expressed as a hazard ratio. However the most important outcome
from an economic perspective is the number (or count) of
recurrences, hence numbers of recurrences are set against the costs
of care, which include management of recurrent cellulitis and
antibiotic prophylaxis (in the active treatment arm). First and
subsequent recurrences were recorded in both trials using the same
clinical reporting mechanism and all were clinically verified as
described within the trial reports [7,8].
Quality of life measures included the EuroQoL EQ-5D-3L [17]
and Dermatitis Life Quality Index, DQLI [18]. The EuroQoL
EQ-5D-3L is a generic quality of life measure with 5 domains each
scored at 3 levels: findings are mapped onto societal health state
preference values referenced to scores of 0 (dead) and 1 (perfect
health). The Dermatology Life Quality Index (DLQI) is a disease
specific quality of life measure including 10 questions each with 4
levels (0–3) scored from 0 (no effect) to 30 (extremely large effect
on quality of life). Although we attempted to collect quality of life
data during the trial at the time of recurrences, this was often
unsuccessful due to a time lag in being notified of the event.
However these measures were assessed for patients during and
after resolution of their index infection at baseline (before
commencement of trial prophylaxis). From these data, the
reduction in DLQI and quality-adjusted life-years due to a
recurrence were estimated, comparing measures to demonstrate
consistency. The QALY loss due to recurrence at baseline was
used to model QALY gains due to recurrence prevention during
the trial phase. Effective treatment normally makes cellulitis a
short-lived event lasting 7–10 days [4]. As a result, the impact on
participants’ quality of life was estimated using index episode data,
providing a QALY ‘tariff’ for a recurrence.
Resource Use and Cost
Patient diaries were used to capture numbers of days spent in
hospital, outpatient visits, community nurse contacts, GP consul-
tations, prescriptions and time off work or away from routine
activities related to the treatment of cellulitis and its sequelae (e.g.
ulcers or lymphedema). These were then reported to the trial team
during scheduled telephone follow-up contacts (at 3 or 6 monthly
intervals depending on the stage of the trial). Recurrent episodes
were confirmed by clinical consultation with either the study
investigator or the participant’s general practitioner at the time of
the recurrence. Episodes that were unable to be confirmed by a
medical professional were excluded from the analysis. National
unit costs for 2010 were applied to resources providing a cost of
care for each patient during follow-up. Outpatient visits,
community nurse contacts and GP consultations were costed at
£152, £27 and £36 per item respectively [15]. Hospital
consultations were costed at £319/day - the reference cost [19]
for intermediate skin disorders category two obtained by mapping
the ICD10 code for cellulitis (L03) to the HRG code JD03 [20].
Prescriptions were costed using prices provided in the British
National Formulary [6]. Time away from work or normal
activities was costed at £110/day using the Annual Survey of
Hours and Earnings (ASHE) [21]. The societal perspective
included all reported cost items; costs of time away from work
or normal activities were excluded for the NHS perspective.
Analysis
Although prophylaxis periods were 12 months and 6 months in
the PATCH I and PATCH II trials respectively, a common
treatment period of 12 months (with post treatment of up to 24
months) was used to structure the data for comparability and
analytic convenience. Since cost data and recurrence data are
highly skewed, treatment group differences and confidence
intervals were estimated stochastically using bootstrap methods
with 1,000 replications per estimate (i.e. resampling the patient-
level data with replacement) [22]. For counts of recurrence,
incident rate ratios were estimated conservatively using a
generalised linear model using the negative binomial with log link
function. Cost-effectiveness planes were generated and used to
generate cost-effectiveness acceptability curves (CEACs) using
standard methods [23]. The CEAC, derived from the joint
distribution of costs and effects, illustrates the (Bayesian) proba-
bility that the data are consistent with an underlying (true) level of
cost-effectiveness, precluding a simple frequentist interpretation of
probability values. The primary analysis included combined
patient-level from both the PATCH I and II trials. The effect of
discounting costs and benefits was explored using discount rates of
0%, 3.5% and 5% with the primary analysis estimating future
costs and benefits discounted at 3.5%, in line with NICE Guidance
[24]. In addition to discounting, the influence of outlier values,
analyses of individual trial findings and a model of continuous
prophylaxis were explored in sensitivity analyses. Analyses were
performed in SPSS 21 2012 IBM Corporation and Excel v14 
2010 Microsoft Corporation.
Results
Patient Characteristics
The characteristics of patients recruited into the PATCH I and
II trials have been previously reported. In brief, there were no
differences between groups in either trial at baseline. PATCH I
patients were: median age 58 (IQR 48–67); 66% female; BMI 33
(IQR: 28–40); 100% had a history of recurrent cellulitis, 68% had
pre-existing oedema, ulcer or both. PATCH II patients were:
Prophylactic Antibiotics for Leg Cellulitis
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median age 59 (IQR 48–71); 66% female; BMI 31 (IQR: 27–36);
21% had a history of recurrent cellulitis, 51% had pre-existing
oedema, ulcer or both.
Recurrence
There was a consistent pattern of relative benefit in the two
trials over 3 years of follow-up, although findings from PATCH II
did not reach statistical significance, due to limited power. The
relative rate of recurrence expressed as the incident rate ratio
(IRR) was consistent between trials showing similar benefit in the
first year but no persisting protective effect in years 2 and 3 (see
Figure 1). Overall there was a 29% reduction in the number of
recurrences occurring within the trial (IRR: 0.71, 95%CI: 0.53 to
0.90, p= 0.02), corresponding to an absolute reduction of
recurrence of 0.31 recurrences/patient (95%CI: 0.05 to 0.59,
p = 0.02).
Quality of Life
EQ-5D and DLQI scores were obtained during a screening visit
and again at 10 days post randomisation for a random subsample
of patients: complete data from both periods were available for
200 patients. At the screening visit, participants were categorised
as either having an ongoing episode of cellulitis (n = 71), or having
had a recent episode of cellulitis that had subsequently resolved
(n = 129). Consequently EQ-5D and DLQI scores could be
compared in patients during and after infection with a comparison
group with no contemporaneous infection. Table 1 shows similar
scores when comparing screening and 10 day findings in the no
infection group but significant improvement in the patients
undergoing treatment for infection. Applying an average of 7
days infection and a 26.3% reduction in quality of life, a
recurrence is approximately worth 0.26367/365 of 0.005
QALYS. (This is taken as approximately equivalent to a infection
time-varying in severity over ten days where quality of life
improves once antibiotic therapy takes effect). Consequently a
reduction of 0.305 recurrences/patient is worth approximately
0.0015 QALYs. Qualitatively DLQI scores provided a similar
finding with no clinically significant differences in the two periods
for the no infection group but improvement by nearly 10 points in
the infection group.
Costs Analysis
Resource items contributing to costs are reported in Table 2.
No resource items differed significantly comparing antibiotic and
placebo groups for the combined trials or for the individual trials.
Unit costs were applied to resources use and together with drug
costs provided overall NHS treatment costs. Societal costs included
a valuation of time away from normal activities. Consistent with
the resource data there were no significant NHS or societal cost
differences between groups.
Incremental Cost-Effectiveness
Patient-level data were bootstrapped and visualised on the cost-
effectiveness plane (Figure 2, NHS costs). The distribution of
replicates shows a mean cost saving of £197 and reduction in
recurrence of 0.303 per patient, with future costs and benefits
discounted at 3.5%. Thus on average antibiotic prophylaxis was
cost saving while reducing recurrences.
The cost-effectiveness acceptability curve (CEAC) was generat-
ed (the proportion of replicates to the south and west as a line
sweeps anticlockwise from the x-axis to the y-axis on the cost-
effectiveness plane) and is shown in Figure 3. The CEAC indicates
the probability that prophylaxis is cost-effective for a range of cost-
effectiveness ratios values. The two x-axes show cost per
recurrence and cost/QALY. If a decision-maker is willing to pay
up to £25,000/QALY (shown as a dashed line, the middle of the
range £20–30K/QALY used in England by NICE as assess value
for money [24]), then there is a 66% probability of this being true
from an NHS perspective and 76% probability from a secondary,
societal perspective. Investing for lower returns (or a higher cost/
QALY), it becomes increasingly probable that antibiotic prophy-
laxis is cost-effective. If a break-even (no-investment) criterion is
required then prophylaxis is 62% likely to be cost-effective from an
NHS perspective and 73% from a secondary, societal perspective.
Discounting
Discounting had little effect upon any of the incremental
estimates of cost, effect or cost-effectiveness estimates reported (see
Table 2).
Figure 1. Analysis of recurrence rates in the PATCH trials, exploring on-prophylaxis, post-prophylaxis and overall rates.
doi:10.1371/journal.pone.0082694.g001
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Sensitivity Analysis
Sensitivity analyses included the influence of outlier values,
separate analyses of the PATCH I and II trials and modelling of
continuous prophylaxis.
Individual trials and outlier values. Four patients within
the two trials had very high, cellulitis-related costs during the trial
and there was evidence of raised health service usage before
enrolment in these patients. Two such patients were present in the
placebo group of PATCH II and two in the antibiotic group in
PATCH I, thus apparently increasing the cost-effectiveness of
PATCH II and reducing the cost-effectiveness of PATCH I.
Figure 4 shows the individual trial CEACs with and without the
outlier patients: the individual trial findings converge to the pooled
finding for PATCH 1 and II. Removal of further higher cost
patients or high recurrence patients from either trial had no
qualitative or systematic impact on findings.
Continuous prophylaxis. There was a more dramatic 45%
reduction in the number of recurrences while on prophylaxis
(incident rate ratio, IRR: 0.55 95%CI: 0.37 to 0.80), p = 0.002 (see
Figure 1). It was possible to approximate continuous prophylaxis
Table 1. Effect of cellulitis on quality of life.
t0* t1*
mean (sd) mean (sd) N t1–t0 (95%CI) p
EQ-5D
No Infection+ 0.733 (0.264) 0.746 (0.296) 125 0.013 (20.025 to 0.051) 0.50
Infection# 0.436 (0.342) 0.699 (0.291) 70 0.263 (0.180 to 0.352) ,0.001
DLQI
No Infection+ 5.15 (5.51) 3.72 (4.74) 129 21.43 (22.31 to 20.54) 0.001
Infection 14.11 (8.09) 4.56 (4.81) 71 29.55 (211.50 to 27.83) ,0.001
*Baseline trial visits: t0 = screening visit, t1 = trial visit at day 10.
+Patient with no infection at t0.
#Patient with infection at t0.
doi:10.1371/journal.pone.0082694.t001
Table 2. Resource use, cost and outcome in the combined PATCH trials.
Antibiotic, N=196 Placebo, N=201
Mean (SD) Mean (SD) D* (95% CI ) p
GP visits 3.41 (17.90) 2.84 (11.64) 0.57 (22.20 to 3.68) 0.76
Community nurse visits 6.61 (44.32) 2.13 (14.10) 4.48 (21.08 to 11.64) 0.22
Inpatient stays 0.16 (0.56) 0.15 (0.55) 0.00 (20.11 to 0.11) 0.94
Inpatient days 0.98 (3.66) 2.06 (15.25) 21.08 (23.59 to 0.53) 0.46
Outpatient visits 0.41 (1.63) 0.61 (3.04) 20.19 (20.73 to 0.23) 0.46
Days off work 3.17 (14.98) 5.10 (19.61) 21.94 (25.38 to 1.33) 0.27
Drugs cost+
Study, rc = 0% 29.82 2 0.00 2 29.82 (28.63 to 30.95) ,0.001
Non-study, rc = 0% 16.22 (65.32) 18.23 (55.86) 22.01 (214.49 to 9.80) 0.76
NHS treatment cost+
rc = 0% 722 (2090) 927 (4931) 2205 (21049 to 402) 0.63
rc = 3.5% 704 (2034) 900 (4768) 2197 (21009 to 387) 0.63
rc = 5% 696 (2011) 889 (4702) 2193 (2992 to 384) 0.63
Societal Cost+
rc = 0% 1069 (2750) 1486 (6437) 2417 (21479 to 383) 0.48
rc = 3.5% 1047 (2698) 1452 (6240) 2406 (21440 to 375) 0.48
rc = 5% 1038 (2678) 1439 (6159) 2401 (21426 to 371) 0.48
Recurrence rate
rc = 0% 0.755 (1.278) 1.060 (1.434) 2.305 (20.588 to 20.050) 0.02
rc = 3.5% 0.732 (1.233) 1.034 (1.394) 2.303 (20.575 to 20.054) 0.02
rc = 5% 0.722 (1.215) 1.024 (1.378) 2.302 (20.572 to 20.056) 0.02
*D: Antibiotic – Placebo.
+2010 costs; rc refers to the discount rates applied to costs distributed over time.
doi:10.1371/journal.pone.0082694.t002
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by modelling the cost and recurrence data to one year and
excluding subsequent post-treatment data. The assumption made
is that benefit and cost profiles within the first year are stable and
persistent. Modelling one-year data produced virtually identical
findings to the main analysis, which might be expected since the
net costs and benefits after one year are not significantly altered
after three years.
Discussion
Main Findings
Antibiotic prophylaxis substantially reduced the number of
recurrences experienced by patients while on treatment although
there was no evidence of a persisting protective effect when
therapy ceased. There was no evidence of a ‘rebound’ with a
compensating greater frequency of cellulitis after cessation of
antibiotic treatment, thus there may be a case for extending
antibiotic treatment to prolong benefit, as occurs in current clinical
practice in the management of individual patients.
Antibiotic prophylaxis as a policy for treatment following either
first episode or recurrent cellulitis is likely to be cost-effective to the
NHS, although CEAC analysis shows this finding is on balance of
probability (66%) rather than with conventional of statistical
certainty (90% or 95%). This finding is largely a consequence of
large variations in patient costs, leading to imprecise cost-
effectiveness estimates. Consequently, the incremental cost effec-
tiveness of penicillin prophylaxis couples a precise estimate of
benefit (98% probability of net benefit) with greater cost
uncertainty (62% probability of net cost savings). Notwithstanding
these uncertainties, these two trials together provide the best
evidence currently available to explore a policy of prophylaxis
(tailored by duration of treatment) to first episode and recurrent
cellulitis.
While post hoc secondary analysis of the PATCH I trial
confirmed that patients with a high BMI, multiple previous
episodes and/or lymphedema of the leg had substantially greater
risk of recurrence, there was no interaction with the efficacy of
treatments. Overall findings for number of recurrence (not
tabulated) similarly showed no significant interaction between
these variables and treatment. Thus there is currently no evidence
to target prophylaxis to patients on the basis of these risk profiles
[25].
Strengths and Weaknesses
The economic analysis of the PATCH I and PATCH II was
planned according to a prospectively defined protocol in which
these trials were to be analysed separately. However PATCH II
under-recruited, and cost data from both trials was imprecise
(reducing the ability of the individual trial economic analyses to be
informative). Comparison of recurrence and cost findings provided
a valid basis for a combined analysis. Consequently the economic
analysis addresses the policy relevant question of should antibiotic
prophylaxis (of appropriate duration) be offered to patients
following first episode or recurrent cellulitis. When conducting a
patient level analysis of the two trials combined, the analysis
maintains the protection against bias provided within the
randomised controlled design. However, this does provide an
arbitrary weighting of overall findings, reflecting the numbers of
patients in the two trials.
Patients were asked to collect and report information on
cellulitis-related resource use. Thus there was a risk of under-
reporting, although the randomised design provides some protec-
tion against systematic differences between groups.
The value of preventing an episode of cellulitis in terms of
QALYs gained was approximated using screening and baseline
DLQI scores in those with and without ongoing cellulitis at the
time of trial recruitment. The QALY estimate is likely to be
conservative, since some patients may have already been
recovering at the screening visit and some patients may have
had ongoing infection at the baseline visit, typically ten days later.
Thus it is possible that the likelihood of cost-effectiveness has been
underestimated although this would not alter the findings of the
analysis qualitatively. By inspection of Figure 3, a doubling of the
QALY gain per recurrence would increase the likelihood of cost-
effectiveness at a threshold of £25,000 from 66% to 72%.
Figure 2. Cost-effectiveness plane (NHS costs and benefits
discounted at 3.5%).
doi:10.1371/journal.pone.0082694.g002
Figure 3. Cost-effectiveness acceptability curves (CEACs), NHS
and Societal costs and benefits discounted at 3.5%.
doi:10.1371/journal.pone.0082694.g003
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Generalizability
PATCH I and II were pragmatically designed to reflect normal
clinical care, with minimal contact between patients and recruiting
clinicians. Trial design features (e.g. appropriately generated
randomisation, use of double-blinding and low dropout rates)
are likely to have minimised bias. Baseline characteristics of trial
participants were representative of the spread of patients routinely
seen in the UK and Ireland. These results should generalise well to
patients in countries other than the UK with similar healthcare
systems and where overall levels of hospitalisation are low.
Implications for Practice
Economic analysis of the PATCH trials suggests that a policy of
antibiotic prophylaxis is likely, on balance, to be cost-effective for
patients both with first episode and recurrent cellulitis. The clinical
implication is that antibiotic prophylaxis reduces cellulitis recur-
rence by nearly a third and is not associated with a significant
increase in cost.
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